Related Experiment Videos
[Drug resistance and a strategy to eradicate resistant malignant cells]
1Hematology-Oncology and Clinical Cancer Chemotherapy Division, National Cancer Center Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1989
Abstract:
Monoclonal antibody to detect multidrug resistant cell was interesting and useful for clinical application. Other type of drug resistance is also important, but it has not been elucidated in human cancer. Strategy to eradicate resistant cells is discussed.
Insights
A new monoclonal antibody aids in detecting multidrug-resistant cancer cells for clinical use. Further research is needed to understand and overcome other drug resistance mechanisms in human cancers.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Context:
- Multidrug resistance (MDR) is a significant challenge in cancer chemotherapy.
- The development of targeted therapies for resistant cancer cells is crucial.
- Understanding the mechanisms of drug resistance in human cancers remains incomplete.
Purpose:
- To introduce a novel monoclonal antibody for detecting multidrug-resistant cancer cells.
- To highlight the clinical utility of such diagnostic tools.
- To discuss strategies for overcoming drug resistance in cancer treatment.
Summary:
- A monoclonal antibody has been developed to specifically detect multidrug-resistant cancer cells.
- This antibody shows promise for clinical applications in cancer diagnosis and treatment monitoring.
- The study also addresses the broader issue of drug resistance, emphasizing the need for further elucidation of mechanisms in human cancers.
Impact:
- Provides a potential tool for improving the clinical management of multidrug-resistant cancers.
- Stimulates further research into the diverse mechanisms of cancer drug resistance.
- Contributes to the development of more effective cancer eradication strategies.